Premium
ACALABRUTINIB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: FINAL RESULTS FROM A PHASE 2 STUDY
Author(s) -
Wang M.,
Rule S.,
Zinzani P. L.,
Goy A.,
Casasnovas O.,
Smith S. D.,
Damaj G.,
Doorduijn J. K.,
Lamy T.,
Morschhauser F.,
Panizo C.,
Shah B.,
Davies A.,
Eek R.,
Dupuis J.,
Jacobsen E.,
Kater A. P.,
Gouill S.,
Oberic L.,
Robak T.,
Jain P.,
Calvo R.,
Tao L.,
DlugoszDanecka M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.58_2880
Subject(s) - mantle cell lymphoma , medicine , gastroenterology , refractory (planetary science) , phases of clinical research , ibrutinib , oncology , diffuse large b cell lymphoma , progression free survival , bruton's tyrosine kinase , lymphoma , toxicity , surgery , overall survival , leukemia , chronic lymphocytic leukemia , tyrosine kinase , physics , receptor , astrobiology